Showing results (1291-1300 of 4,880) with videos related to

Sort By:
Pageof 488
Urologic Oncology|August 30, 2025
Morbidity and mortality of salvage radical prostatectomy for prostate cancer: An analysis of the National surgical quality improvement program targeted prostatectomy databaseVatsala Mundra, Renil Sinu Titus, Eusebio Luna, et al.
Urologic Oncology|August 30, 2025
Disparities in radiation treatment modality for prostate cancerMitchell Alameddine, Shan Wu, Oluwaseun Orikogbo, et al.
Urologic Oncology|August 26, 2025
Outcomes of endoscopic management for upper tract urothelial carcinoma: A multi-center international cohort analysisJaime O Herrera-Caceres, Marian Wettstein, Surena F Matin, et al.
Urologic Oncology|May 25, 2015
Decreased PBRM1 expression predicts unfavorable prognosis in patients with clear cell renal cell carcinomaSoo Jeong Nam, Cheol Lee, Jeong Hwan Park, et al.
Urologic Oncology|May 9, 2015
MicroRNA-429 suppresses cell proliferation, epithelial-mesenchymal transition, and metastasis by direct targeting of BMI1 and E2F3 in renal cell carcinomaMingning Qiu, Ziji Liang, Lieqian Chen, et al.
Urologic Oncology|May 20, 2015
Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogationDaniele Raggi, Luigi Mariani, Patrizia Giannatempo, et al.
Urologic Oncology|May 21, 2015
Commentary on: "Satisfaction with information used to choose prostate cancer treatment." Gilbert SM, Sanda MG, Dunn RL, Greenfield TK, Hembroff L, Klein E, Saigal CS, Pisters L, Michalski J, Sandler HM, Litwin MS, Wei JT. H. Lee Moffitt Cancer Center, Tampa, Florida; Department of Urology, Emory University, Atlanta, Georgia; Department of Urology, University of Michigan, Ann Arbor, Michigan; Department of Psychiatry and Public Health Institute, University of California-San Francisco, California; Institute for Public Policy and Social Research, Michigan State University, Lansing, Michigan; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio; Department of Urology and Department of Health Policy and Management, University of California-Los Angeles, Los Angeles, California; Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston, Texas; Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri; Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, California.: J Urol 2014;191(5):1265-71. doi:10.1016/j.juro.2013.12.008. [Epub 2013 Dec 12]Hollenbeck Brent
Urologic Oncology|May 17, 2015
Expression of cell cycle regulators, 14-3-3σ and p53 proteins, and vimentin in canine transitional cell carcinoma of the urinary bladderAlejandro Suárez-Bonnet, Pedro Herráez, Maria Aguirre, et al.
Urologic Oncology|April 15, 2020
Neoadjuvant versus adjuvant chemotherapy for upper tract urothelial carcinomaAlberto Martini, Ugo Giovanni Falagario, Nikhil Waingankar, et al.
Urologic Oncology|April 15, 2020
Role of miRNAs in prostate cancer: Do we really know everything?Giovanni Cochetti, Jacopo Adolfo Rossi de Vermandois, Vincenza Maulà, et al.
Pageof 488